Trial reportFrontiers in cardiovascular medicine2025
Anthracycline-induced cardiotoxicity associated with myocardial energy metabolism: mechanisms revealed through an integration of
Trial report in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Early prediction of synergistic cardiotoxicity induced by PD-1 inhibitors and doxorubicin using cardiacChinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Targeting phosphofructokinase in cancer: integrating natural products for metabolic reprogramming and therapeutic innovation.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: Anthracyclines, as a type of chemotherapy drugs, are widely used in the first-line treatment of cancers. However, anthracycline-induced cardiotoxicity (AIC) in the cumulative and dose-dependent manner greatly limits the clinical application. Insufficient energy supply caused by myocardial metabolic reconstruction is an established factor for AIC. At present, the left ventricular maximum standardized uptake value (LV SUV Methods: A total of 30 patients with diffuse large B-cell lymphomas and treated with anthracycline-based chemotherapy in the Hematology Department of Jiangsu Province Hospital of Chinese Medicine from December 2023 to December 2024 were enrolled. Finally, 17 participants were included as the Diffuse Large B-cell Lymphoma (DLBCL) group. Additionally, 13 non-oncologic participants without organic heart disease, who required Results: Among 17 patients in the DLBCL group, 6 received epirubicin chemotherapy with an average dose of 59.28 ± 12.54 mg/m Conclusion: An integration of Clinical Trial Registration: https://www.chictr.org.cn/, identifier ChiCTR2400088740.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.